These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22512565)

  • 1. NK-1 receptor antagonists: a new generation of anticancer drugs.
    Munoz M; Covenas R
    Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NK-1 receptor: a new target in cancer therapy.
    Muñoz M; Rosso M; Coveñas R
    Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer progression and substance P.
    Coveñas R; Muñoz M
    Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new frontier in the treatment of cancer: NK-1 receptor antagonists.
    Muñoz M; Rosso M; Coveñas R
    Curr Med Chem; 2010; 17(6):504-16. PubMed ID: 20015033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
    Muñoz M; Coveñas R
    Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
    Muñoz M; Martinez-Armesto J; Coveñas R
    Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK-1 receptor antagonists: a new paradigm in pharmacological therapy.
    Muñoz M; Coveñas R
    Curr Med Chem; 2011; 18(12):1820-31. PubMed ID: 21466470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
    Muñoz M; Coveñas R
    World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
    Muñoz M; Coveñas R
    Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
    Muñoz M; Coveñas R
    Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of substance P and the NK-1 receptor in cancer progression.
    Muñoz M; Coveñas R
    Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
    Munoz M; Recio S; Rosso M; Redondo M; Covenas R
    J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
    Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
    Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
    Rosso M; Muñoz M; Berger M
    ScientificWorldJournal; 2012; 2012():381434. PubMed ID: 22545017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.